Voyager Therapeutics, Inc. - 8-K Summary
Business Context and Reporting Period
This Form 8-K Current Report, dated June 3, 2025, covers the results of the 2025 Annual Meeting of Stockholders held on that date. Voyager Therapeutics, Inc. (VYGR), a Delaware corporation, reported on corporate governance matters, including director elections, executive compensation votes, auditor ratification, and the approval of equity incentive plans.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance and stockholder voting outcomes rather than financial performance metrics.
Material Changes and Voting Results
Stockholders approved several key proposals and elected new directors. Notable voting outcomes include:
- Director Elections: Grace E. Colón, Catherine J. Mackey, Glenn Pierce, and George Scangos were elected as Class I directors. George Scangos received the highest number of withheld votes (6,720,399) compared to his peers.
- Executive Compensation: The non-binding advisory vote on executive compensation passed with 37,755,432 votes for and 2,034,622 against.
- Auditor Ratification: Ernst & Young LLP was ratified as the independent registered public accounting firm for the fiscal year ending December 31, 2025, with overwhelming support (48,137,216 for vs. 249,172 against).
- Equity Plans: The 2025 Stock Incentive Plan was approved (28,582,188 for vs. 11,275,604 against). The Amended and Restated 2015 Employee Stock Purchase Plan was also approved (36,532,540 for vs. 3,326,824 against).
Guidance, Outlook, and Risks
The filing text does not provide a clear value for future guidance, management commentary on business outlook, specific risks, or contingencies. The document serves as a procedural record of the annual meeting.
Investor Verification Checklist
- Verify the specific terms and share limits of the newly approved 2025 Stock Incentive Plan (Exhibit 99.1).
- Review the details of the Amended and Restated 2015 Employee Stock Purchase Plan (Exhibit 99.2).
- Monitor the tenure of the newly elected Class I directors, who serve until the 2028 Annual Meeting.
- Confirm the significant number of broker non-votes (8,531,070) recorded across multiple proposals, which may indicate institutional voting patterns.